PHARMACY

Galderma to purchase GollaGenex for $420 million

BY Drew Buono

NEWTOWN, Pa. CollaGenex Pharmaceuticals has agreed to be acquired by Galderma Laboratories in a deal worth about $420 million, according to published reports. The board of directors of CollaGenex and Galderma unanimously approved the transaction.

CollaGenex manufactures the drug Oracea for the treatment of rosacea and is also developing Col-118, for the treatment of the erythema associates with rosacea.

“Galderma was the first pharmaceutical company to develop a topical product indicated for the treatment of rosacea,” Colin Stewart, president and chief executive officer of CollaGenex, said. “Oracea, combined with the successful development of Col-118, will enable Galderma to offer physicians and patients a full suite of complementary pharmaceutical products to treat rosacea.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

CARE Pharmacies moves headquarters to share space with NCPA

BY Michael Johnsen

ALEXANDRIA, Va. CARE Pharmacies, a conglomerate of independent drug stores operating primarily in and around the nation’s capital, on Monday announced its moving in with the National Community Pharmacy Association, relocating its corporate headquarters from Arlington, Va. the next town over to Old Town Alexandria, Va., where it will share space with the NCPA.

“We are excited about many areas in which CARE is partnering with NCPA,” stated Gerry Crocker, CARE chief executive officer. “Our being located in their headquarters will have its obvious advantages as our relationship develops,” he said.

CARE relocated its headquarters as part of its expansion efforts—where additional office space and staff are required, the company stated.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Eric Leeds appointed senior vp at Mylan

BY Drew Buono

PITTSBURGH Mylan has appointed Eric Leeds as senior vice president and head of global investor relations.

Leeds has more than 20 years of experience with capital markets. Most recently, he was senior vice president and head of investor relations at Primedia. While there, he broadened his knowledge of investor awareness by taking part in 18 acquisitions and the sale of closing of 25 businesses.

Mylan vice chairman and chief executive officer Robert Coury said: “As a significantly larger, global company, we recognize the importance of best-in-class communications and transparency and are pleased that Eric has joined our executive team to further strengthen our communications with the investment community. Eric’s strong financial background, combined with his international experience, knowledge of mergers and acquisitions and leverage, and in-depth understanding of the investment community will be invaluable in helping Mylan continue to grow its businesses and leadership positions around the world.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?